JPWO2020113029A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020113029A5 JPWO2020113029A5 JP2021530101A JP2021530101A JPWO2020113029A5 JP WO2020113029 A5 JPWO2020113029 A5 JP WO2020113029A5 JP 2021530101 A JP2021530101 A JP 2021530101A JP 2021530101 A JP2021530101 A JP 2021530101A JP WO2020113029 A5 JPWO2020113029 A5 JP WO2020113029A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- tgfbrii
- cish
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims 45
- 102100012246 CISH Human genes 0.000 claims 31
- 101700087259 CISH Proteins 0.000 claims 31
- 210000002865 immune cell Anatomy 0.000 claims 26
- 102100006047 TIGIT Human genes 0.000 claims 22
- 101700052319 TIGIT Proteins 0.000 claims 22
- -1 PDL-2 Proteins 0.000 claims 21
- 102100013078 CD47 Human genes 0.000 claims 13
- 101700033237 CD47 Proteins 0.000 claims 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- 102100017339 KLRC1 Human genes 0.000 claims 13
- 101710036388 KLRC1 Proteins 0.000 claims 13
- 101710004393 HAVCR2 Proteins 0.000 claims 12
- 102100016384 HAVCR2 Human genes 0.000 claims 12
- 102100014435 CD96 Human genes 0.000 claims 11
- 101710026045 CD96 Proteins 0.000 claims 11
- 101700086090 AGL1 Proteins 0.000 claims 10
- 102100015476 FOXO1 Human genes 0.000 claims 10
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 claims 10
- 102100003367 PTPN6 Human genes 0.000 claims 10
- 101710033203 PTPN6 Proteins 0.000 claims 10
- 101710035063 SHP1 Proteins 0.000 claims 10
- 101710043085 ADAM17 Proteins 0.000 claims 9
- 102100010284 ADAM17 Human genes 0.000 claims 9
- 102100004476 SIRPA Human genes 0.000 claims 9
- 101710024246 SIRPA Proteins 0.000 claims 9
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 9
- 102100011528 ADORA2A Human genes 0.000 claims 8
- 101710039842 ADORA2A Proteins 0.000 claims 8
- 229920000033 CRISPR Polymers 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 238000010354 CRISPR gene editing Methods 0.000 claims 7
- 102100004479 SIGLEC7 Human genes 0.000 claims 7
- 101710045220 SIGLEC7 Proteins 0.000 claims 7
- 210000004700 Fetal Blood Anatomy 0.000 claims 6
- 238000004520 electroporation Methods 0.000 claims 6
- 101710040446 CD40 Proteins 0.000 claims 5
- 102100013137 CD40 Human genes 0.000 claims 5
- 102100005828 CD5 Human genes 0.000 claims 5
- 101700066525 CD5 Proteins 0.000 claims 5
- 108091008153 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 102100003994 TGFBR2 Human genes 0.000 claims 5
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 102100019451 CD80 Human genes 0.000 claims 4
- 101700080477 CD80 Proteins 0.000 claims 4
- 108010042407 Endonucleases Proteins 0.000 claims 4
- 101700079540 FAS Proteins 0.000 claims 4
- 102100016439 FAS Human genes 0.000 claims 4
- 229920002391 Guide RNA Polymers 0.000 claims 4
- 108020005004 Guide RNA Proteins 0.000 claims 4
- 102100004115 ICAM1 Human genes 0.000 claims 4
- 101700051176 ICAM1 Proteins 0.000 claims 4
- 102100015897 IL10RA Human genes 0.000 claims 4
- 101710032882 IL10RA Proteins 0.000 claims 4
- 102100005025 IL21R Human genes 0.000 claims 4
- 101700082799 IL2RA Proteins 0.000 claims 4
- 102100000618 INPP5D Human genes 0.000 claims 4
- 101710005390 INPP5D Proteins 0.000 claims 4
- 101700015336 ISG20 Proteins 0.000 claims 4
- 102100002950 ISG20 Human genes 0.000 claims 4
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 4
- 108060004270 LAG3 Proteins 0.000 claims 4
- 102100017213 LAG3 Human genes 0.000 claims 4
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 claims 4
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 claims 4
- 102100017740 NR3C1 Human genes 0.000 claims 4
- 101710024111 NR3C1 Proteins 0.000 claims 4
- 102100001964 RPS6 Human genes 0.000 claims 4
- 101710029097 RPS6 Proteins 0.000 claims 4
- 108060007796 SPATA2 Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 101700045617 pdl-1 Proteins 0.000 claims 4
- 101710008334 rps602 Proteins 0.000 claims 4
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 3
- 101700025368 ERBB2 Proteins 0.000 claims 3
- 102100016662 ERBB2 Human genes 0.000 claims 3
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 3
- 102100018522 SNCA Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000001185 Bone Marrow Anatomy 0.000 claims 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 101700086956 IFNG Proteins 0.000 claims 2
- 102100016020 IFNG Human genes 0.000 claims 2
- 102100008150 IL2RG Human genes 0.000 claims 2
- 101700011716 IL2RG Proteins 0.000 claims 2
- 210000000581 Natural Killer T-Cells Anatomy 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710023234 Segment 5 Proteins 0.000 claims 2
- 101710040448 TNFRSF4 Proteins 0.000 claims 2
- 102100013135 TNFRSF4 Human genes 0.000 claims 2
- 230000000259 anti-tumor Effects 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 210000004475 gamma-delta T lymphocyte Anatomy 0.000 claims 2
- 230000006867 granzyme B production Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000033064 perforin production Effects 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000002688 persistence Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 210000002707 regulatory B cell Anatomy 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 230000001177 retroviral Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000002142 suicide Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 108009000283 Allograft Rejection Proteins 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100010454 CD200 Human genes 0.000 claims 1
- 101710024588 CD200 Proteins 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 102100005830 CD70 Human genes 0.000 claims 1
- 101700017377 CD70 Proteins 0.000 claims 1
- 102100016532 CD99 Human genes 0.000 claims 1
- 108060001253 CD99 Proteins 0.000 claims 1
- 102100011842 CEACAM5 Human genes 0.000 claims 1
- 102100013153 CLEC12A Human genes 0.000 claims 1
- 101710010518 CLEC12A Proteins 0.000 claims 1
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims 1
- 101700026160 CSPG4 Proteins 0.000 claims 1
- 102100002013 CSPG4 Human genes 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 102000033180 ERVK-6 Human genes 0.000 claims 1
- 101710038044 ERVK-6 Proteins 0.000 claims 1
- 101710027967 ERVW-1 Proteins 0.000 claims 1
- 101710044633 FCER1G Proteins 0.000 claims 1
- 102100007619 FCER1G Human genes 0.000 claims 1
- 101700053597 FCER2 Proteins 0.000 claims 1
- 102100014608 FCER2 Human genes 0.000 claims 1
- 101700060135 GNMT Proteins 0.000 claims 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 241000192019 Human endogenous retrovirus K Species 0.000 claims 1
- 102100018760 IL3RA Human genes 0.000 claims 1
- 101700029869 IL3RA Proteins 0.000 claims 1
- 210000000987 Immune System Anatomy 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102100013180 KDR Human genes 0.000 claims 1
- 101710030888 KDR Proteins 0.000 claims 1
- 101700047455 KTI1 Proteins 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 102100006037 MUC1 Human genes 0.000 claims 1
- 101700052761 MUC1 Proteins 0.000 claims 1
- 102100006044 MUC16 Human genes 0.000 claims 1
- 101700008449 MUC16 Proteins 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 101700077124 NCAM1 Proteins 0.000 claims 1
- 102100007544 NCAM1 Human genes 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 102100017729 ROR1 Human genes 0.000 claims 1
- 101710036428 ROR1 Proteins 0.000 claims 1
- 101700058902 RORA Proteins 0.000 claims 1
- 101710042981 SHMT1 Proteins 0.000 claims 1
- 102100012981 TNFRSF10A Human genes 0.000 claims 1
- 101710030971 TNFRSF10A Proteins 0.000 claims 1
- 101710030862 TNFRSF13C Proteins 0.000 claims 1
- 102100009743 TNFRSF13C Human genes 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 102100019730 TP53 Human genes 0.000 claims 1
- 101710026335 TP53 Proteins 0.000 claims 1
- 108060008723 TYROBP Proteins 0.000 claims 1
- 102100008188 TYROBP Human genes 0.000 claims 1
- 102100014338 ZNF654 Human genes 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 102000003735 mesothelin Human genes 0.000 claims 1
- 108090000015 mesothelin Proteins 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 101700042113 tap Proteins 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862772406P | 2018-11-28 | 2018-11-28 | |
| US62/772,406 | 2018-11-28 | ||
| PCT/US2019/063641 WO2020113029A2 (en) | 2018-11-28 | 2019-11-27 | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513652A JP2022513652A (ja) | 2022-02-09 |
| JPWO2020113029A5 true JPWO2020113029A5 (ru) | 2022-11-21 |
Family
ID=69005890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530101A Pending JP2022513652A (ja) | 2018-11-28 | 2019-11-27 | 機能および抑制性環境に対する抵抗性を増強するための免疫細胞のマルチプレックスゲノム編集 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220031749A1 (ru) |
| EP (1) | EP3887518A2 (ru) |
| JP (1) | JP2022513652A (ru) |
| KR (1) | KR20210096638A (ru) |
| CN (1) | CN113272427A (ru) |
| AU (1) | AU2019386140A1 (ru) |
| BR (1) | BR112021010297A2 (ru) |
| CA (1) | CA3121027A1 (ru) |
| EA (1) | EA202191463A1 (ru) |
| IL (1) | IL283428A (ru) |
| MX (1) | MX2021006208A (ru) |
| SG (1) | SG11202105609RA (ru) |
| WO (1) | WO2020113029A2 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021013219A (es) * | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos. |
| CA3140393A1 (en) * | 2019-06-04 | 2020-12-10 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| AU2020388690A1 (en) * | 2019-11-20 | 2022-06-09 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
| AU2021369476A1 (en) * | 2020-10-26 | 2023-06-08 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| JP2023546652A (ja) * | 2020-10-27 | 2023-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性が増強されたナチュラルキラー細胞 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| CN116783286A (zh) * | 2021-01-20 | 2023-09-19 | 阿维塔斯有限公司 | Rnps向免疫细胞的顺序传递 |
| EP4039808A1 (en) * | 2021-02-08 | 2022-08-10 | Ospedale San Raffaele S.r.l. | Guide rnas and uses thereof |
| WO2022242701A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified gamma-delta t cells and uses thereof |
| WO2022242700A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified nk cells and uses thereof |
| AU2021469314A1 (en) * | 2021-10-19 | 2024-03-14 | Peter Maccallum Cancer Institute | Compositions and methods for immunotherapy |
| WO2023081900A1 (en) * | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| WO2023092020A2 (en) * | 2021-11-17 | 2023-05-25 | The Regents Of The University Of California | Gene targets for t-cell-based immunotherapy to overcome suppressive factors |
| WO2023215278A1 (en) * | 2022-05-03 | 2023-11-09 | The Broad Institute, Inc. | Modified immune cells and methods for use thereof |
| WO2024076750A2 (en) * | 2022-10-07 | 2024-04-11 | Whitehead Institute For Biomedical Research | Engineered macrophages for use in treating cancer |
| EP4353741A1 (en) * | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| WO2024100203A1 (en) * | 2022-11-10 | 2024-05-16 | Onk Therapeutics Limited | Combined therapies using immunomodulating drugs |
| CN116590237B (zh) * | 2023-05-29 | 2023-10-31 | 上海贝斯昂科生物科技有限公司 | 一种遗传修饰的自然杀伤细胞及其制备和用途 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6416998B1 (en) | 1992-09-02 | 2002-07-09 | Baylor College Of Medicine | Plasmid encoding a modified steroid hormone |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| AU7326594A (en) | 1993-07-09 | 1995-02-06 | Synergen, Inc. | Recombinant ctla4 polypeptides and methods for making the same |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US6461867B1 (en) | 1995-03-08 | 2002-10-08 | The Scripps Research Institute | Synthetic antigen presenting matrix |
| US5763270A (en) | 1995-06-07 | 1998-06-09 | Genemedicine, Inc. | Plasmid for delivery of nucleic acids to cells and methods of use |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| AU723355B2 (en) | 1996-05-23 | 2000-08-24 | Scripps Research Institute, The | MHC class II antigen presenting systems and methods for activating CD4+ T cells |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CA2584482C (en) | 1998-02-05 | 2012-03-27 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
| CA2343156A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| CZ303703B6 (cs) | 1998-12-23 | 2013-03-20 | Pfizer Inc. | Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1287357A2 (en) | 2000-06-02 | 2003-03-05 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7989425B2 (en) | 2002-09-27 | 2011-08-02 | Genexine Inc. | Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| DK3196296T3 (en) | 2004-09-08 | 2019-02-04 | Wisconsin Alumini Res Foundation | Cultivation of human embryonic stem cells |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| JP2009515529A (ja) | 2005-11-14 | 2009-04-16 | メリアル リミテッド | 腎不全のための遺伝子療法 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| CN101356270B (zh) | 2005-12-13 | 2014-02-12 | 国立大学法人京都大学 | 核重新编程因子 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| AU2007222080B2 (en) | 2006-03-01 | 2012-08-16 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| ES2603418T3 (es) | 2006-10-04 | 2017-02-27 | Janssen Pharmaceutica Nv | Preparación de células presentadoras de antígeno artificial inactivado y su uso en terapias celulares |
| US8440461B2 (en) | 2007-03-23 | 2013-05-14 | Wisconsin Alumni Research Foundation | Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constituent expression of costimulatory ligands on indirectly transmitted T lymphocytes |
| PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
| US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| JP2011522540A (ja) | 2008-06-04 | 2011-08-04 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| CN107988261A (zh) | 2008-08-12 | 2018-05-04 | 细胞动力国际有限公司 | 产生ips细胞的方法 |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| US8268620B2 (en) | 2008-10-24 | 2012-09-18 | Wisconsin Alumni Research Foundation | OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells |
| JP2012528599A (ja) | 2009-06-05 | 2012-11-15 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | リプログラミングｔ細胞および造血細胞 |
| US8900871B2 (en) | 2009-08-07 | 2014-12-02 | Kyoto University | Method of producing induced pluripotent stem cells using inhibitors of P53 |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| CA2777710C (en) | 2009-11-04 | 2021-02-23 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US9005967B2 (en) | 2010-01-22 | 2015-04-14 | Kyoto University | Myc variants improve induced pluripotent stem cell generation efficiency |
| ES2826894T3 (es) | 2010-02-19 | 2021-05-19 | Xencor Inc | Nuevas inmunoadhesinas CTLA4-IG |
| CN103003416B (zh) | 2010-06-15 | 2016-11-16 | 细胞动力学国际有限公司 | 从小体积的外周血产生诱导性多潜能干细胞 |
| CN107699585A (zh) | 2010-12-09 | 2018-02-16 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| US9447194B2 (en) | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| CN107557334B (zh) | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| EA201492222A1 (ru) | 2012-05-25 | 2015-05-29 | Селлектис | Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| IL269270B (en) | 2012-08-20 | 2022-07-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| KR102198058B1 (ko) | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US9597357B2 (en) * | 2012-10-10 | 2017-03-21 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| JP2016524464A (ja) * | 2013-05-13 | 2016-08-18 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のために高活性ｔ細胞を操作するための方法 |
| CA2917858A1 (en) | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| PT3702373T (pt) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico |
| GB2595063B (en) * | 2015-07-31 | 2022-03-09 | Univ Minnesota | Modified cells and methods of therapy |
| EP3526235A4 (en) * | 2016-10-12 | 2021-03-10 | Feldan Bio Inc. | RATIONALLY DESIGNED SYNTHETIC PEPTIDE SHUTTLE ACTIVE INGREDIENTS FOR ADMINISTRATION OF POLYPEPTIDE FREIGHT FROM AN EXTRACELLULAR ROOM TO THE CYTOSOL AND / OR THE CORE OF AN EUCARYOTIC TARGET CELL, USES TOGETHER THEREFORE, AND KITS IN THE PROCEDURE |
| WO2018115189A1 (en) * | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| WO2019106163A1 (en) * | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
-
2019
- 2019-11-27 EA EA202191463A patent/EA202191463A1/ru unknown
- 2019-11-27 WO PCT/US2019/063641 patent/WO2020113029A2/en active Application Filing
- 2019-11-27 EP EP19827952.3A patent/EP3887518A2/en active Pending
- 2019-11-27 CN CN201980088334.XA patent/CN113272427A/zh active Pending
- 2019-11-27 CA CA3121027A patent/CA3121027A1/en active Pending
- 2019-11-27 AU AU2019386140A patent/AU2019386140A1/en active Pending
- 2019-11-27 JP JP2021530101A patent/JP2022513652A/ja active Pending
- 2019-11-27 SG SG11202105609RA patent/SG11202105609RA/en unknown
- 2019-11-27 KR KR1020217019926A patent/KR20210096638A/ko unknown
- 2019-11-27 MX MX2021006208A patent/MX2021006208A/es unknown
- 2019-11-27 BR BR112021010297-3A patent/BR112021010297A2/pt unknown
- 2019-11-27 US US17/309,408 patent/US20220031749A1/en active Pending
-
2021
- 2021-05-25 IL IL283428A patent/IL283428A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020113029A5 (ru) | ||
| US20200370012A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2019176869A5 (ru) | ||
| RU2688185C2 (ru) | Способ и композиции для клеточной иммунотерапии | |
| US20220339193A1 (en) | Modified Cell Expressing Therapeutic Agent and Uses thereof | |
| TW202134264A (zh) | 嵌合抗原受體及其用途 | |
| US20220008464A1 (en) | Modified t cell, preparation method therefor and use thereof | |
| BR112021003305A2 (pt) | métodos para produzir células que expressam receptor de antígeno quimérico | |
| CN109055380B (zh) | 一种通用型car-t细胞的制备方法 | |
| KR20200015467A (ko) | 범용 항-cd22 키메라 항원 수용체 조작된 면역 세포 | |
| TW201502139A (zh) | Ｃｄ１９特異性嵌合抗原受體及其用途 | |
| US11834502B2 (en) | Reducing immune inhibition induced by SIGLEC-15 | |
| JP2002524081A (ja) | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 | |
| US20210161961A1 (en) | Modified Cell Expressing Therapeutic Agent and Uses thereof | |
| CA3090249A1 (en) | Combination therapy using a chimeric antigen receptor | |
| CN112771167A (zh) | 表达有趋化因子的细胞及用途 | |
| EP4138864A1 (en) | Polyspecific binding molecules and their use in cell therapy | |
| CN112680419A (zh) | 嵌合抗原受体细胞分泌治疗剂 | |
| CN110819596B (zh) | 具有增强的迁移能力的修饰的细胞 | |
| CN112779223B (zh) | 偶联嵌合抗原受体细胞及其用途 | |
| US11981920B2 (en) | Modified cell with enhanced migration capability | |
| US20230032871A1 (en) | Recombinant Viral Particle for Gene and/or Cellular Therapy | |
| TW201927812A (zh) | 醫藥重組受體組成物及方法 | |
| US11788072B2 (en) | Activation of APC in immunotherapy | |
| EP4203980A1 (en) | Fusion protein enhancing cell therapy |